PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
HOME > REGULATORY
REGULATORY
- New Working Group to Propose Effective Collection and Sharing of Drug Supply Info by March-End
September 12, 2023
- Japan to End Free COVID Vaccine Program in March, Weighs NIP Inclusion
September 11, 2023
- Japan Panel OKs Use of Pfizer’s XBB.1.5 Jab for Fall Vaccination Campaign
September 11, 2023
- PMDA Reviewing Safety Risks for G-CSF Agents, Yervoy and More
September 11, 2023
- MHLW Panel OKs Changes to Guidelines for Using NDB, Anonymized Medical Data
September 11, 2023
- MHLW Moving Toward Allowing Use of Cannabis-Derived Drugs: LDP Session
September 8, 2023
- LDP Lawmakers Deplore Reported GMP Issues at Sawai
September 8, 2023
- MHLW Plans to Consolidate Class 2 and 3 OTC Drugs
September 7, 2023
- Exact Sciences’ SaMD to Assess Breast Cancer Recurrence Risk Listed on Sept. 1
September 7, 2023
- Japan Eyes AI-Driven Drug Discovery Project for Cancer, Intractable Diseases
September 7, 2023
- Japan Unveils 2nd Package Strategy for SaMD
September 7, 2023
- Japan Healthcare Spending Renews Record with 46 Trillion Yen in FY2022
September 6, 2023
- Japan to Soon Start Taking Applications for Antibiotic Revenue Guarantee Program
September 6, 2023
- MHLW to Launch Working Group on Drug Supply Info on Sept. 7
September 5, 2023
- 23 Suspected Violations in Promotion Activities Reported in FY2022: MHLW
September 5, 2023
- Dispensing Pharmacy Chief Nabbed for Obstruction of Public Bid
September 4, 2023
- Japan Launches Agency for Infectious Disease Crisis Management
September 4, 2023
- Relief Claims OK’ed for 54 More Deaths after COVID Vaccination
September 4, 2023
- Japan Approves Pfizer’s Omicron XBB.1.5 Vaccine, Moderna’s Still under Review
September 4, 2023
- MHLW Rejigs Organization, Infectious Disease Control Team Boots Up
September 1, 2023
ページ
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…